Antiaging Quantum Living Inc (AAQL)

[DewDiligence]

More discussion on JNJ/ACHN's HCV regimen: #msg-130785673.

[maverick_1]

Sadly despite the institutional ownership and bloodletting, yet another one that I've posted on that has fallen many stair rungs from their highs: ACHN from the low teens.

Pyrrh & his handful of other alias(ie:micheone; milner etc) is the strike out king in picking stocks..... along with being the king of narcissists and distortionist....... as belatedly acknowledge by many.

Biotecs are richly laden with land mines and science is just one of many complex facets needed to stock picking.

Disappointing mid-stage data for triple combo for HCV-3 sinks Achillion; shares down 12%

Apr. 24, 2017 3:48 PM ET|About: Achillion Pharmaceutic... (ACHN)|By: Douglas W. House, SA News Editor
Achillion Pharmaceuticals (ACHN -12.4%) is on the outside looking in at the market's and biotech's big up move today. Data presented at The International Liver Congress showed a 100% cure rate at weeks 6 and 8 for HCV genotype 1 for the triple combo of simeprevir, odalasvir and AL-335. For HCV genotype 3, though, there was not enough of an efficacy signal to warrant continued development.

The negative result in the most treatment-resistant HCV genotype has spooked investors. Baird wasted little time in adjusting its outlook, cutting the price target in half to $5 (57% upside).

Achillion's odalasvir, an NS5A inhibitor, is being developed by J&J's Janssen Pharmaceuticals under a May 2015 global agreement.

Previously: Triple combo of simeprevir, odalasvir and AL-335 produced 100% cure rate in as little as six weeks in mid-stage HCV study (April 24)

http://ir.achillion.com/releasedetail.cfm?ReleaseID=1022374

[DewDiligence]

JNJ/ACHN’s 3-DAA HCV regimen has a problem: #msg-130712374.

[Optionsrbest4u]

>>Co issues downside guidance for FY17, sees EPS of ($0.75) to ($0.70) vs. ($0.48) Capital IQ Consensus Estimate.
R&D expenses expected between $75 mln and $80 mln
Net cash used in operating activities expected between $70M and $75M<<

[molee]

Analysts called for (-.18) ACHN actual (-.03) ....

Beats the street by .15 and STILL gets hammered ...

Total B S ...

[molee]

Such BS . Totally whacked out .

The stock had a good day on Wednesday , the day before their presentation .

Then today it tanks leading up to the 1:30 pm EST presentation , and into the close .

I don't get it ...

[Joeymc77]

What's happening today... ? this thing is bombing ..!

[molee]

Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017, at 1:30 p.m. ET at the Lotte New York Palace Hotel in New York, NY.

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

[molee]

Buy rating and a $10 price target.

Achillion Pharmaceuticals ( ACHN) shares were up 2.2%, to $4.20.

Ladenburg Thalmann on Thursday initiated coverage of New Haven, Conn.-based Achillion with a buy rating and a $10 price target.

"We see two very clear pathways for significant value creation for investors," wrote Ladenburg analyst Christopher James in a note. "The first is with the ACH-4471 program for multiple rare diseases driven by disorders of the complement system. The second path is through its HCV program, which is partnered with Janssen Pharmaceuticals."

https://www.thestreet.com/story/13976492/1/premarket-biotech-movers-cytokinetics-achillion-qiagen.html?puc=yahoo&cm_ven=YAHOO

[molee]

Trump speech shoot this in the foot today ?

[molee]

ACHN on the move finally ...

Will it stick ? Or continue to stick it to us ?

[Basin Street Blues]

10m is the lowest SI there's been in about 3 years.... days to cover are totally immaterial .

[molee]

No . "They" don't seem concerned ...

[CuzMoneyMatters]

10 mil shares short. Any idea how long til they have to cover?

[molee]

Good news Bad news = SELL

Pathetic ....

[recon1221]

Curse Of The Clay Trader

Bwah HA HA!!!!!

[ClayTrader]

* * $ACHN Video Chart 11-03-16 * *

Link to Video - click here to watch the technical chart video

[willlbone]

Achilles heel crumbles.

[molee]

Stinkhole

[molee]

How many shorts on this I wonder ...

Constant sell pressure .

Will this change going into earnings ??

[molee]

Constant selling . Every day ...

[biotechrocks]

4th Qtr should be an interesting one as J&J and probably a couple of others will need to make a call. A buyout is a strong possibility sooner vs later otherwise the stock price will probably get into double digits before y/e and will make the buyout that much more expensive!

[Basin Street Blues]

Achillion PT $20 Edison

They also provide a free report its very good but even then $20 is too low .

[biotechrocks]

Very nice. All recommendations by the analyst are very positive and these are some very big names! Should be a good 4Q for ACHN and even a better 2017!

[Basin Street Blues]

ACHN Analyst Recommendation

Analyst.....Recommendation.....................................Tgt Px..........Date?

Baird Brian P Skorney ......OUTPERFORM...................$ 10.00.......09/26/16
William Blair & Co...Y Katherine Xu..OUTPERFORM $ 17.00.......09/26/16
FBR ........ Dr Christopher S Jam......OUTPERFORM....$ 16.00.......09/26/16
Jefferies... Brian Abrahams..............HOLD...................$ 7.00.........09/23/16
Wedbush Heather Behanna.............OUTPERFORM....$13.00........09/23/16
Leerink Joseph P Schwartz............Market Perform...... $ 9.00........09/23/16
JMP Securities Liisa A Bayko......Market outperform....$ 13.00........09/23/16

[biotechrocks]

You may be right.....lots of analyst however have a target price of $10 plus prior to Sept end. Let see if we get a pop starting Oct!

[Basin Street Blues]

Market Maker - manipulation , they'll try it on the downside to as close to $8 as they can , then we will run up till Xmas barring any election reactionary move .

[biotechrocks]

Reminder of JNJ & ACHN announcement from May of last year:

Achillion partners with J&J to develop hepatitis C drugs

Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

Achillion will be eligible for milestone payments of up to $1.1 billion related to the development, regulatory approval and sales of the drugs.

Johnson & Johnson will also invest $225 million in Achillion in return for about 18.4 million unregistered shares at $12.25 per share.

Achillion is developing three hepatitis C drugs -- ACH-3102 and sovaprevir in mid-stage trials and ACH-3422 in early-stage trials.

ACH-3102, which was granted fast-track designation in the United States, will be part of the oral regimen that could shorten treatment time to six weeks by 2018, the companies said on a call with analysts.

Gilead Sciences Inc's recently approved pill Harvoni requires at least eight weeks of treatment. The pill combines two of Gilead's other drugs - ledipasvir and sovaldi.

The fight against hepatitis C has made huge gains in recent years. A couple of years ago, patients needed 48 weeks of treatment with drugs that had harsh side effects. They cured only about 40 percent of patients.

The new all-oral treatments seek to replace injectable interferon and its flu-like side effects as well as an older drug called ribavirin that caused anemia and other problems.

[biotechrocks]

Took a position yesterday and feel the news from Friday will resonate starting this coming week. ACHN has plenty of cash and may also be in a good position to be a buyout candidate. Should be a double digit stock very soon in my opinion.

[ClayTrader]

* * $ACHN Video Chart 09-23-16 * *

Link to Video - click here to watch the technical chart video

[girlfriend]

Was hoping for a spike over the 52 week high….but nice still

[PLelek]

$$$$$$$

[artmaniac]

loving the spike here!

[trendmkr]

Biotech Movers: Lantheus Holdings and Achillion Pharmaceuticals http://marketexclusive.com/biotech-movers-9/32318/?icd1

[stocktrademan]

ACHN bullish 8.85

nasdaq stocks $1-10 with volume > 100,000

[lgonber]

Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
- Results support initiation of phase 1 multiple-ascending trial during the second quarter and phase 2 studies for paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G) by year-end 2016 -
NEW HAVEN, Conn., June 10, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (ACHN) today presented interim results from a phase 1 study with its novel small molecule factor D inhibitor, ACH-4471, at the 21st Congress of the European Hematology Association in Copenhagen, Denmark.
The e-poster entitled, "An Orally Administered Small Molecule Factor D Inhibitor (ACH-4471) For Treatment of PNH, C3G and Complement – Mediated Diseases: Interim Phase 1 Results In Healthy Volunteers” describes results from an ongoing phase 1 study led by Roderick B. Ellis-Pegler and Christian Schwabe of Auckland Clinical Studies Ltd, Auckland, New Zealand and a group of researchers from Achillion.
Across all four groups, ACH-4471 achieved peak plasma concentrations between 1 and 2.5 hours after oral dosing. Up to 100% inhibition of complement activity was achieved in all dose groups, and duration of inhibition was dose dependent. In addition, Group 4, which evaluated 1,200 mg of ACH-4471 given every twelve hours for 2 doses, achieved a median 99.5% inhibition (range 96 – 100%) of hemolysis at 24 hours.
"We are very encouraged by these data, which support our focus on developing potent, specific factor D inhibitor compounds, including ACH-4471, as a potentially novel approach to treating alternative pathway complement-mediated diseases such as PNH and C3G,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. “Achieving sustained suppression of AP activity, as measured by the AP hemolysis and Wieslab assays, combined with modeling from these interim study results, suggest the potential for twice daily dosing to achieve sustained inhibition of AP activity."
The phase 1 study, initiated in February 2016, aims to assess the safety and tolerability of single ascending oral doses of ACH-4471 in healthy volunteers and to evaluate its pharmacokinetic (PK) and pharmacodynamic (PD) profile and PK/PD relationship as measured by the serum alternative pathway (AP) activity ex vivo.
In the study, 36 subjects have been dosed and evaluated. Trial participants were assigned to one of four groups:
Group 1: 200 mg, single dose (6 active + 6 placebo subjects)
Group 2: 600 mg, single dose (6 active + 2 placebo subjects)
Group 3: 1200 mg, single dose (6 active + 2 placebo subjects)
Group 4: 1200 mg x 2 doses (Q12H) (6 active + 2 placebo subjects)
For all groups, inhibition of serum AP activity was evaluated using the AP Wieslab and hemolysis assays. Blood samples were collected from days 1 through 7 to determine plasma concentrations. Trial participants were monitored through the last scheduled visit at day 28 for any adverse events.
The interim study data indicate ACH-4471 was well-tolerated at all dose levels examined with no safety trends noted. Evaluation of serum AP activity by ex vivo assessment suggests rapid inhibition of AP activity after oral dosing. Furthermore, the concentrations of Bb, the cleavage product of factor B by factor D, were determined for the assessment of the inhibitory effect of ACH-4471 on in vivo factor D activity. Bb levels were shown to decline after dosing with ACH-4471 with the lowest Bb levels observed at 16 hours post-dosing in Groups 3 and 4 and a gradual return to baseline by 48 hours after dosing.
Achillion plans to begin dosing in a phase 1 multiple-ascending dose study evaluating 14-days of dosing in healthy volunteers in June. The Company is also planning to initiate phase 2 studies of ACH-4471 in two complement-mediated diseases, PNH and C3G, by the end of 2016.
Abstracts for the 2016 Congress of the European Hematology Association are available online and can be accessed at http://www.ehaweb.org/. A reprint of the late breaking poster presentation will be available from the Resources section of the Achillion website at http://www.achillion.com.
About the Achillion Complement Factor D Platform
Achillion has leveraged its internal discovery capabilities and a novel complement-related platform to develop drug candidates that are oral inhibitors of complement factor D. Factor D is an essential serine protease involved in the complement pathway, a part of the innate immune system. Achillion's complement platform is focused on seeking to advance small molecule compounds that inhibit factor D and can potentially be used in the treatment of immune-related diseases in which complement plays a critical role. Potential indications being evaluated for these compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD), and chronic obstructive pulmonary disease (COPD). Achillion anticipates that its platform could play a role in addressing the needs of all PNH patients, including patients who have suboptimal response to, or fail to respond to, the currently available treatments, as well as for patients suffering from other alternative pathway complement-mediated diseases. Achillion nominated ACH-4471 for clinical development in December 2015, and initiated clinical development in February 2016.

[venturecapp]

Achillion Pharmaceuticals To Present Abstract At European Hematology Association

http://marketexclusive.com/achillion-pharmaceuticals-inc-nasdaqachnwill-present-late-breaking-abstract-21st-congress-european-hematology-association/6980/?icd1

[Basin Street Blues]

Yesterdays Bloomberg Professional Pharma Data Calendar

[kwantung07]

Hi BSB,

I've contacted the IR and am waiting for a response. You have something for me from the Bloomberg Professional Pharma Event?

Kwan

[stocktrademan]

$ACHN recent news/filings

bullish 10.28
inverted head and shoulders

## source: finance.yahoo.com

Mon, 21 Dec 2015 21:15:09 GMT ~ Bristol-Myers Inks Deal to Sell HIV Pipeline to ViiV Healthcare


read full: http://finance.yahoo.com/news/bristol-myers-inks-deal-sell-211509595.html
*********************************************************

Mon, 21 Dec 2015 13:35:01 GMT ~ Strength Seen in Sequenom (SQNM): Stock Jumps 5% in Session


read full: http://finance.yahoo.com/news/strength-seen-sequenom-sqnm-stock-133501369.html
*********************************************************

Mon, 21 Dec 2015 13:00:00 GMT ~ Today's Market Driven by Key Factors -- Research on Tumi Holdings, Meritor, Achillion Pharmaceuticals and Geron

[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Tumi Holdings ...

read full: http://finance.yahoo.com/news/todays-market-driven-key-factors-130000166.html
*********************************************************

Wed, 16 Dec 2015 21:32:08 GMT ~ Achillion Appoints Dr. Frank Verwiel to Board of Directors

[at noodls] - NEW HAVEN, Conn., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive Officer of ...

read full: http://www.noodls.com/view/FB51BED40EEE51B611C91FAFE2E7D60CAC27942D
*********************************************************

Wed, 16 Dec 2015 21:05:00 GMT ~ Achillion Appoints Dr. Frank Verwiel to Board of Directors

[GlobeNewswire] - NEW HAVEN, Conn., Dec. 16, 2015-- Achillion Pharmaceuticals, Inc. today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive Officer of Aptalis Pharma, to Achillion’ s ...

read full: http://finance.yahoo.com/news/achillion-appoints-dr-frank-verwiel-210500803.html
*********************************************************

$ACHN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ACHN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ACHN/company-info
Ticker: $ACHN
OTC Market Place: Not Available
CIK code: not found
Company name: Achillion Pharmaceuticals, Inc.
Incorporated In: DE, USA

$ACHN share structure

## source: otcmarkets.com

Market Value: $1,383,200,050 a/o Dec 23, 2015
Shares Outstanding: 136,544,921 a/o Nov 01, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$ACHN extra dd links

Company name: Achillion Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ACHN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ACHN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ACHN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/news - http://finance.yahoo.com/q/h?s=ACHN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ACHN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ACHN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ACHN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Achillion+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Achillion+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Achillion+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ACHN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ACHN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ACHN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ACHN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ACHN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ACHN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ACHN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ACHN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ACHN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ACHN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ACHN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ACHN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ACHN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ACHN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ACHN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ACHN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ACHN



$ACHN DD Notes ~ http://www.ddnotesmaker.com/ACHN

[SureFireTrader]

ACHN stock chart view http://stockcharts.com/h-sc/ui

[Basin Street Blues]

19 Trading days till AASLD ...with 26.5m short ....

The shorts are algo shorts correlated to NBI , as ACHN deviates form the daily movements of the NBI
the machines will cut their positions , so in order for this to happen ACHN needs to outperform the NBI on the upside , quite simply as long as we dont go down as much as the NBI may do then the short covering will happen . Next stop $16.85

Short Int close vol ratio
09/30/2015 26,503,651 6.91 3.49 M 7.60
09/15/2015 24,323,333 7.80 2.59 M 9.39
08/31/2015 24,127,918 7.39 3.20 M 7.54
08/14/2015 22,694,313 7.41 2.11 M 10.75
07/31/2015 23,904,689 8.52 2.02 M 11.82
07/15/2015 23,074,183 9.33 2.07 M 11.16
06/30/2015 23,044,887 8.86 2.58 M 8.94
06/15/2015 20,495,335 8.73 3.64 M 5.63
05/29/2015 19,953,645 9.89 7.45 M 2.68
05/15/2015 17,154,648 9.57 2.04 M 8.41
04/30/2015 17,035,994 8.75 2.83 M 6.02
04/15/2015 14,934,880 10.43 1.90 M 7.88
03/31/2015 15,292,215 9.86 2.97 M 5.15
03/13/2015 15,901,640 11.30 4.79 M 3.32
02/27/2015 15,183,025 12.14 5.16 M 2.95
02/13/2015 15,324,965 10.89 8.93 M 1.72
01/30/2015 15,372,422 14.85 4.79 M 3.21
01/15/2015 16,889,722 13.72 4.92 M 3.43
12/31/2014 16,278,569 12.25 11.72 M 1.39
12/15/2014 15,555,923 12.72 4.76 M 3.27

[Turtle65]

Hi RK.... Got your PM...thx soooo much for sharing....I will give it some thought.
Bios are very volatile and risky for sure- yikes !!!

Be interesting how the IBB does for the rest of this year...maybe it will stay above 300 and start climbing...who knows lol

Have a great weekend :)

Keep in touch ...turtle

[Rkmatters]

Agree.

[sorkin]

Now is the Time to accumulate ACHN

[rivervalley]

sold 8.04, and will keep on watch for another buy.

[rivervalley]

vol up over average after 1 hr of trading. Let's see how it plays out today and this week.

[rivervalley]

picked up a starter this morning on the pullback.

[ClayTrader]

* * $ACHN Video Chart 08-17-15 * *

Link to Video - click here to watch the technical chart video

[rusty8350]

Nice to see this moving up again